{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:07:45Z","timestamp":1790276865293,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"the National Basic Research Program of China","award":["2012CB967000"],"award-info":[{"award-number":["2012CB967000"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (CN)","doi-asserted-by":"publisher","award":["30971606 and 30772475"],"award-info":[{"award-number":["30971606 and 30772475"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China (CN)","doi-asserted-by":"publisher","award":["81072047"],"award-info":[{"award-number":["81072047"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hong Kong Research Grant Council Collaborative Research Funds","award":["C7038-14G and C7027-14G"],"award-info":[{"award-number":["C7038-14G and C7027-14G"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2050-6","type":"journal-article","created":{"date-parts":[[2016,1,13]],"date-time":"2016-01-13T18:17:01Z","timestamp":1452709021000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["CD133+ liver cancer stem cells resist interferon-gamma-induced autophagy"],"prefix":"10.1186","volume":"16","author":[{"given":"Jian","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Na","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Peng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yuan","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,1,13]]},"reference":[{"key":"2050_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69\u201390.","journal-title":"CA Cancer J Clin"},{"key":"2050_CR2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jnci\/djs473","volume":"105","author":"JW Elena","year":"2013","unstructured":"Elena JW, Travis LB, Simonds NI, Ambrosone CB, Ballard-Barbash R, Bhatia S, et al. Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research. J Natl Cancer Inst. 2013;105:85\u201394.","journal-title":"J Natl Cancer Inst"},{"key":"2050_CR3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","volume":"31","author":"G Kroemer","year":"2013","unstructured":"Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51\u201372.","journal-title":"Annu Rev Immunol"},{"key":"2050_CR4","doi-asserted-by":"crossref","unstructured":"El-Deiry WS. Impact of genetic targets on cancer therapy. Forward. Adv Exp Med Biol. 2013;779:v-vi.","DOI":"10.1007\/978-1-4614-6176-0"},{"key":"2050_CR5","unstructured":"Masuda S, Izpisua Belmonte JC. The microenvironment and resistance to personalized cancer therapy. Nat Rev Clin Oncol. 2013;10: doi:10.1038\/nrclinonc."},{"key":"2050_CR6","doi-asserted-by":"crossref","first-page":"e0016","DOI":"10.1667\/RROL02.1","volume":"176","author":"PM Glazer","year":"2013","unstructured":"Glazer PM, Grandis J, Powell SN, Brown JM, Helleday T, et al. Radiation resistance in cancer therapy. Radiat Res. 2013;176:e0016\u201321.","journal-title":"Radiat Res"},{"key":"2050_CR7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12094-007-0004-9","volume":"9","author":"I Martinez-Lacaci","year":"2007","unstructured":"Martinez-Lacaci I, Garcia Morales P, Soto JL, Saceda M. Tumour cells resistance in cancer therapy. Clin Transl Oncol. 2007;9:13\u201320.","journal-title":"Clin Transl Oncol"},{"key":"2050_CR8","first-page":"3225","volume":"118","author":"C Printz","year":"2012","unstructured":"Printz C. Radiation treatment generates therapy-resistant cancer stem cells from less aggressive breast cancer cells. Cancer. 2012;118:3225.","journal-title":"Cancer"},{"key":"2050_CR9","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","volume":"486","author":"S Misale","year":"2012","unstructured":"Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature. 2012;486:532\u20136.","journal-title":"Nature"},{"issue":"Suppl 1","key":"2050_CR10","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/bja\/aes421","volume":"109","author":"A Heaney","year":"2012","unstructured":"Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth. 2012;109 Suppl 1:i17\u201328.","journal-title":"Br J Anaesth"},{"key":"2050_CR11","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.2174\/138161212799859701","volume":"18","author":"JA McCubrey","year":"2012","unstructured":"McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Basecke J, et al. Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr Pharm Des. 2012;18:1784\u201395.","journal-title":"Curr Pharm Des"},{"key":"2050_CR12","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.2741\/e531","volume":"4","author":"B Malik","year":"2012","unstructured":"Malik B, Nie D. Cancer stem cells and resistance to chemo and radio therapy. Front Biosci. 2012;4:2142\u20139.","journal-title":"Front Biosci"},{"key":"2050_CR13","first-page":"340","volume":"2","author":"Y Hu","year":"2012","unstructured":"Hu Y, Fu L. Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res. 2012;2:340\u201356.","journal-title":"Am J Cancer Res"},{"key":"2050_CR14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13277-011-0155-8","volume":"32","author":"S Soltanian","year":"2011","unstructured":"Soltanian S, Matin MM. Cancer stem cells and cancer therapy. Tumour Biol. 2011;32:425\u201340.","journal-title":"Tumour Biol"},{"key":"2050_CR15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.semradonc.2008.11.004","volume":"19","author":"L Milas","year":"2009","unstructured":"Milas L, Hittelman WN. Cancer stem cells and tumor response to therapy: current problems and future prospects. Semin Radiat Oncol. 2009;19:96\u2013105.","journal-title":"Semin Radiat Oncol"},{"key":"2050_CR16","first-page":"278","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M. Cancer stem cells: implications for cancer causation and therapy resistance. Discov Med. 2005;5:278\u201382.","journal-title":"Discov Med"},{"key":"2050_CR17","first-page":"644","volume":"17","author":"I Cetin","year":"2003","unstructured":"Cetin I, Topcul M. Cancer stem cells in oncology. J Buon. 2003;17:644\u20138.","journal-title":"J Buon"},{"key":"2050_CR18","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907\u201317.","journal-title":"Lancet"},{"key":"2050_CR19","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1053\/j.gastro.2007.04.025","volume":"132","author":"S Ma","year":"2007","unstructured":"Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem\/progenitor cells. Gastroenterology. 2007;132:2542\u201356.","journal-title":"Gastroenterology"},{"key":"2050_CR20","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bbrc.2006.10.128","volume":"351","author":"A Suetsugu","year":"2006","unstructured":"Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem\/progenitor cells. Biochem Biophys Res Commun. 2006;351:820\u20134.","journal-title":"Biochem Biophys Res Commun"},{"key":"2050_CR21","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1038\/sj.onc.1210811","volume":"7","author":"S Ma","year":"2008","unstructured":"Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt\/PKB survival pathway. Oncogene. 2008;7:1749\u201358.","journal-title":"Oncogene"},{"key":"2050_CR22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2011.10.012","volume":"315","author":"LS Piao","year":"2012","unstructured":"Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, et al. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett. 2012;315:129\u201337.","journal-title":"Cancer Lett"},{"key":"2050_CR23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-immunol-031210-101324","volume":"29","author":"MD Vesely","year":"2011","unstructured":"Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235\u201371.","journal-title":"Annu Rev Immunol"},{"key":"2050_CR24","first-page":"3399","volume":"61","author":"C Nakajima","year":"2001","unstructured":"Nakajima C, Uekusa Y, Iwasaki M, Yamaguchi N, Mukai T, Gao P, et al. A role of interferon-gamma (IFN-gamma) in tumor immunity: T cells with the capacity to reject tumor cells are generated but fail to migrate to tumor sites in IFN-gamma-deficient mice. Cancer Res. 2001;61:3399\u2013405.","journal-title":"Cancer Res"},{"key":"2050_CR25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/35074122","volume":"410","author":"V Shankaran","year":"2001","unstructured":"Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107\u201311.","journal-title":"Nature"},{"key":"2050_CR26","doi-asserted-by":"crossref","first-page":"6488","DOI":"10.4049\/jimmunol.163.12.6488","volume":"163","author":"A Kubota","year":"1999","unstructured":"Kubota A, Lian RH, Lohwasser S, Salcedo M, Takei F. IFN-gamma production and cytotoxicity of IL-2-activated murine NK cells are differentially regulated by MHC class I molecules. J Immunol. 1999;163:6488\u201393.","journal-title":"J Immunol"},{"key":"2050_CR27","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.4049\/jimmunol.181.4.2446","volume":"181","author":"M Moreno","year":"2008","unstructured":"Moreno M, Molling JW, von Mensdorff-Pouilly S, Verheijen RH, Hooijberg E, Kramer D, et al. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. J Immunol. 2008;181:2446\u201354.","journal-title":"J Immunol"},{"key":"2050_CR28","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S1074-7613(00)80218-6","volume":"2","author":"Z Qin","year":"2000","unstructured":"Qin Z, Blankenstein T. CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity. 2000;2:677\u201386.","journal-title":"Immunity"},{"key":"2050_CR29","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.4049\/jimmunol.180.5.3132","volume":"180","author":"AA Lugade","year":"2008","unstructured":"Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180:3132\u20139.","journal-title":"J Immunol"},{"key":"2050_CR30","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.4049\/jimmunol.177.5.3004","volume":"177","author":"JA Hollenbaugh","year":"2006","unstructured":"Hollenbaugh JA, Dutton RW. IFN-gamma regulates donor CD8 T cell expansion, migration, and leads to apoptosis of cells of a solid tumor. J Immunol. 2006;177:3004\u201311.","journal-title":"J Immunol"},{"key":"2050_CR31","first-page":"84","volume":"9","author":"DJ Propper","year":"2003","unstructured":"Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, et al. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin Cancer Res. 2003;9:84\u201392.","journal-title":"Clin Cancer Res"},{"key":"2050_CR32","first-page":"1407","volume":"110","author":"AE Lukacher","year":"2002","unstructured":"Lukacher AE. IFN-gamma suspends the killing license of anti-tumor CTLs. J Clin Invest. 2002;110:1407\u20139.","journal-title":"J Clin Invest"},{"key":"2050_CR33","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.bbamcr.2006.06.014","volume":"1763","author":"TM Tekautz","year":"2006","unstructured":"Tekautz TM, Zhu K, Grenet J, Kaushal D, Kidd VJ, Lahti JM. Evaluation of IFN-gamma effects on apoptosis and gene expression in neuroblastoma--preclinical studies. Biochim Biophys Acta. 2006;1763:1000\u201310.","journal-title":"Biochim Biophys Acta"},{"key":"2050_CR34","doi-asserted-by":"crossref","first-page":"e28323","DOI":"10.1371\/journal.pone.0028323","volume":"6","author":"CP Chang","year":"2011","unstructured":"Chang CP, Yang MC, Lei HY. Concanavalin A\/IFN-gamma triggers autophagy-related necrotic hepatocyte death through IRGM1-mediated lysosomal membrane disruption. PLoS One. 2011;6:e28323. doi: 10.1371\/journal.pone.0028323 .","journal-title":"PLoS One"},{"key":"2050_CR35","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.stem.2010.11.010","volume":"7","author":"S Ma","year":"2010","unstructured":"Ma S, Tang KH, Chan YP, Lee TK, Kwan PS, Castilho A, et al. miR-130b promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell. 2010;7:694\u2013707.","journal-title":"Cell Stem Cell"},{"key":"2050_CR36","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1074\/jbc.M609876200","volume":"282","author":"M Matsushita","year":"2007","unstructured":"Matsushita M, Suzuki NN, Obara K, Fujioka Y, Ohsumi Y, Inagaki F. Structure of Atg5.Atg16, a complex essential for autophagy. J Biol Chem. 2007;282:6763\u201372.","journal-title":"J Biol Chem"},{"key":"2050_CR37","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ncb1482","volume":"8","author":"S Yousefi","year":"2006","unstructured":"Yousefi S, Perozzo R, Schmid I, Ziemiecki A, Schaffner T, Scapozza L, et al. Calpain-mediated cleavage of Atg5 switches autophagy to apoptosis. Nat Cell Biol. 2006;8:1124\u201332.","journal-title":"Nat Cell Biol"},{"key":"2050_CR38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.1992.10.5.735","volume":"10","author":"JW Greiner","year":"1992","unstructured":"Greiner JW, Guadagni F, Goldstein D, Smalley RV, Borden EC, Simpson JF, et al. Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells. J Clin Oncol. 1992;10:735\u201346.","journal-title":"J Clin Oncol"},{"key":"2050_CR39","first-page":"1073","volume":"34","author":"Y Kanda","year":"1988","unstructured":"Kanda Y, Futatsugi K, Saifuku K, Kuwatsuru R, Akazawa S, Fujiki T, et al. Antitumoral effect of gamma-interferon in patients with hepatocellular carcinoma. Gan No Rinsho. 1988;34:1073\u20138.","journal-title":"Gan No Rinsho"},{"key":"2050_CR40","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1002\/cncr.10520","volume":"94","author":"JH Wang","year":"2002","unstructured":"Wang JH, Wu QD, Bouchier-Hayes D, Redmond HP. Hypoxia upregulates BCL-2 expression and suppresses interferon-gamma induced antiangiogenic activity in human tumor derived endothelial cells. Cancer. 2002;94:2745\u201355.","journal-title":"Cancer"},{"key":"2050_CR41","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/1753425913488227","volume":"20","author":"CY Wang","year":"2014","unstructured":"Wang CY, Chiang TH, Chen CL, Tseng PC, Chien SY, Chuang YJ, et al. Autophagy facilitates cytokine-induced ICAM-1 expression. Innate Immun. 2014;20:200\u201313.","journal-title":"Innate Immun"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2050-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T13:29:11Z","timestamp":1692192551000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomedcentral.com\/1471-2407\/16\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,13]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2050"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2050-6","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,13]]},"article-number":"15"}}